Galenvs Announces an Agreement with The Government of Canada to Provide Reagents Required for COVID-19 Testing
MONTREAL, June 23, 2020 – Montreal-based biotechnology provider Galenvs Sciences Inc. “Galenvs”, today announces that the Canadian Federal Government has signed an agreement with Galenvs to supply functionalized magnetic reagents for Coronavirus RNA extraction necessary to enable the COVID-19 testing efforts across Canada.
Galenvs is producing magnetic-based reagents specifically designed for Coronavirus RNA extraction methodologies used in all federal research institutions. The agreement follows a Letter of Intent issued to Galenvs from The Canadian Government to supply The Canadian Government with a key material for COVID-19 testing.
Based in Montreal, Quebec, Galenvs is uniquely positioned to help in the Canadian COVID-19 response as the only Canadian developer and manufacturer of AI-powered, magnetic-based purification and extraction kits for clinical and life sciences research & diagnostics.
“I’m happy to provide a quick update on our work to developing testing and personal protective equipment capacity in Canada,” said Navdeep Bains, Minister of Innovation, Science and Industry, in a press update brief on June 17th, 2020. “We have signed a contract with Galenvs Sciences in Montreal for the production of magnetic reagents, which is a critical input for COVID-19 testing in Canadian labs.”
On June 17th, 2020, Canadian Prime Minister Justin Trudeau also announced the agreement with Galenvs in a statement regarding the measures taken for the COVID-19 challenge:
“We are also working very hard to ensure that hospitals and front-line workers have the equipment and supplies they need. And I have some good news to share on that front,” reads the statement. “[O]ur government signed an agreement with Montréal-based Galenvs to produce magnetic reagents, which are essential for testing.”
“Galenvs has been working hand-in-hand with the exceptional research team at the National Microbiology Laboratory for several months to develop an optimal reagent solution for high-yield RNA extraction,” said Jamal Daoud, President of Galenvs. “We are proud to supply an essential piece of the Coronavirus extraction puzzle, and we’re actively ramping up production capacity to meet the large scale COVID-19 testing objectives.”